Novo Nordisk's Sogroya Gets Positive EU Opinion for Children With Idiopathic Short Stature
MT Newswires Live
Yesterday
Novo Nordisk (NVO) said Friday the European Medicines Agency's CHMP recommended once-weekly Sogroya for children with idiopathic short stature and persistent growth disturbance.
If approved by the European Commission, Sogroya would become the first and only growth hormone treatment approved for idiopathic short stature in the EU, the company said.
The recommendation follows earlier CHMP support for Sogroya in children born small for gestational age and those with Noonan syndrome, it added.
The European Commission's decision on marketing authorization covering all three indications is expected later this year, Novo Nordisk said.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.